K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice
Open Access
- 26 February 2021
- Vol. 9 (3), 195
- https://doi.org/10.3390/vaccines9030195
Abstract
KRAS G12A somatic point mutation in adenocarcinomas is categorized clinically as ineligibility criteria for anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies. In this study, a modified G12A-K-ras epitope (139A) with sequence-specific modifications to improve immunogenicity was developed as a potential vaccine against G12A-mutant KRAS cancers. Additionally, coupling of the 139A epitope with a tetanus toxoid (TTD) universal T-cell epitope to improve antigenicity was also reported. To facilitate convenient oral administration, Lactococcus lactis, which possesses innate immunomodulatory properties, was chosen as a live gastrointestinal delivery vehicle. Recombinant L. lactis strains secreting a G12A mutated K-ras control and 139A with and without TTD fusion were generated for comparative immunogenicity assessment. BALB/c mice were immunized orally, and high survivability of L. lactis passage through the gastrointestinal tract was observed. Elevations in B-cell count with a concomitant titre of antigen-specific IgG and interferon-γ secreting T-cells were observed in the 139A treated mice group. Interestingly, an even higher antigen-specific IgA response and interferon-γ secreting T-cell counts were observed in 139A-TTD mice group upon re-stimulation with the G12A mutated K-ras antigen. Collectively, these results indicated that an antigen-specific immune response was successfully stimulated by 139A-TTD vaccine, and a TTD fusion was successful in further enhancing the immune responses.Keywords
Funding Information
- Ministry of Higher Education (FRGS/1/2017/STG05/UCSI/03/2)
- Ministry of Science Technology and Innovation (02-02-22-SF0011, Proj-In-FAS-061)
This publication has 68 references indexed in Scilit:
- Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine modelMicrobial Cell Factories, 2013
- Mimotope vaccine efficacy gets a "boost" from native tumor antigensOncoImmunology, 2013
- Response definition criteria for ELISPOT assays revisitedCancer Immunology, Immunotherapy, 2010
- Clinical Relevance of KRAS in Human CancersJournal of Biomedicine and Biotechnology, 2010
- Mimotope vaccination – from allergy to cancerExpert Opinion on Biological Therapy, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Archiv, 2008
- Cancer vaccines: on the threshold of successEmerging Drugs, 2008
- Mimotope vaccines: Epitope mimics induce anti-cancer antibodiesImmunology Letters, 2007
- Efficient production and secretion of bovine β-lactoglobulin by Lactobacillus caseiMicrobial Cell Factories, 2007